Skip to main content
Predicting cytomegalovirus with CMV-specific T-cells
15, Nov 2016

Predicting Cytomegalovirus Viremia… With CMV-Specific T-cells

Predicting cytomegalovirus viremia after liver or intestine transplantation (LTx, ITx) with CMV-specific T-cell subsets.

Identifying recipients who may experience CMV viremia after liver or intestine transplantation can potentially enhance decision making about the need for, and the timing and length of prophylactic antiviral therapy. Host immunity to CMV can be measured with CMV-specific T-cells, which express CD40 ligand or CD154(CD154+T-cells). Whether this immunity is best detected with a particular T-cell subset in clinical subjects is less known.

Read more at Abstract 28 on


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.